We are pleased to announce our second conference on genetic perturbations at scale. The development of CRISPR/Cas-based technologies and DNA synthesis make it possible to modulate genomes with relative ease. These tools can help us understand how genetic variation influences phenotype and thereby answer long-standing questions in biology that impact human health, laying the foundations for precision medicine for heritable diseases and cancer treatment.
This rapid advancement in gene-editing technology enables us to begin to understand the functional implications of natural and disease-related human genetic variation. This year’s programme will cover approaches that modulate the genome and its context at scale, from single nucleotides and genes to hundreds of growth environments.
The conference will bring together biomedical researchers working on high throughput screening, genome engineering, and/or variant effect interpretation.
Kenneth Baille – University of Edinburgh, UK
Kristen Brennand – Ichan School of Medicine at Mount Sinai, USA
Barak Cohen – Washington University School of Medicine, USA
Maitreya Dunham – University of Washington, USA
Tom Ellis – Imperial College London, UK
Matthew Garnett – Wellcome Sanger Institute, UK
Jay Hesselberth – University of Colorado School of Medicine, USA
Rory Johnson – University College Dublin, Ireland
Joanna Loizou – CeMM Research Center for Molecular Medicine, Austria
Nozomu Yachie – University of Tokyo, Japan
Sylvie Noordermeer – Leiden University Medical Centre, The Netherlands
Shondra Pruett-Miller – St Judes Children’s Research Hospital, USA
Lea Starita – University of Washington, USA
Wensheng Wei – Peking University, China